Atlas Trials

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Clinical trial NCT01416155 · COMPLETED

Trial details

NCT number
NCT01416155
Sponsor
Biogen
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Start date
2010-10-01
Primary completion
2014-12-01
Enrollment
97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.